Company intelligence / Profile preview
Interius BioTherapeutics
Philadelphia, Pennsylvania, United Statesinteriusbio.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
Interius BioTherapeutics has developed a proprietary lentivector-based gene delivery platform enabling the direct creation of chimeric antigen receptor (CAR) T and NK cells within the patient’s body ("in vivo"), bypassing traditional ex vivo cell manipulation. Their lead candidate, INT2104, targets CD7 to generate anti-CD20 CAR T/NK cells for B-cell malignancies. Preclinical data show complete depletion of human B-cells and tumor elimination in mouse models after a single IV dose; safety demonstrated in nonhuman primate studies. The approach aims to improve accessibility, reduce toxicity, and speed up treatment compared to conventional cell therapies.
- Therapeutic areas
- OncologyHematology
- Modalities
- Lentiviral vectors (LENTIVECTOR platform)In vivo CAR-T and CAR-NK cell generationGenetic medicines/gene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Interius BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interius BioTherapeutics.